Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
22.59
-0.19 (-0.83%)
At close: Sep 18, 2026, 4:00 PM EDT
22.19
-0.40 (-1.77%)
After-hours: Sep 18, 2026, 7:30 PM EDT
Damora Therapeutics Employees
Damora Therapeutics had 7 employees as of December 31, 2025. The number of employees increased by 2 or 40.00% compared to the previous year.
Employees
7
Change (1Y)
2
Growth (1Y)
40.00%
Revenue / Employee
n/a
Profits / Employee
-$34,464,286
Market Cap
1.39B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7 | 2 | 40.00% |
| Dec 31, 2024 | 5 | -8 | -61.54% |
| Dec 31, 2023 | 13 | -32 | -71.11% |
| Dec 31, 2022 | 45 | 5 | 12.50% |
| Dec 31, 2021 | 40 | 12 | 42.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Ascentage Pharma Group International | 828 |
| Alpha Tau Medical | 121 |
| ORIC Pharmaceuticals | 111 |
| Cullinan Therapeutics | 109 |
| ArriVent BioPharma | 77 |
| Savara | 70 |
| Avalyn Pharma | 55 |
DMRA News
- 17 days ago - Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Damora Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Damora Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - Damora Therapeutics Slides: Corporate presentation - Filings
- 6 weeks ago - Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - GlobeNewsWire
- 7 weeks ago - Damora Therapeutics price target raised to $40 from $35 at Wedbush - TheFly
- 7 weeks ago - Damora Therapeutics initiated with a Buy at Jefferies - TheFly
- 2 months ago - Damora Therapeutics completes redomestication to the Cayman Islands - TheFly